SESSION VI: MULTIPLE MYELOMA

Session Chairs: Thomas Martin and Angela Dispenzieri

Frontline Therapy – Quads for Everyone? TE/TI | Ajay K Nooka, MD, MPH, FACP | Emory University, Winship Cancer Institute, Atlanta, Georgia, USA

Debate: CART Will Best Be Used in Early Relapse | Krina K Patel, MD, MSc | MD Anderson Cancer Center, Houston, Texas, USA

Debate: CART Should Be Reserved for Late Relapse > 3 Lines | Saad Z Usmani, MD, MBA, FACP | Memorial Sloan Kettering Cancer Center, New York, New York, USA

Definition and Treatment of HR – NDMM and Functional HR | Suzanne Lentzsch, MD, PhD | Columbia University, New York, New York, USA

Treatment of Early Relapse – Non CAR T Cell | Meletios A Dimopoulos, MD | National and Kapodistrian University of Athens School of Medicine, Athens, Greece

Bispecific Engagers – Sequencing – BCMA, GPTC and Resistance | Amrita Y Krishnan, MD, FACP | City of Hope Comprehensive Cancer Center, Duarte, California, USA

MM Therapy in Resource Constrained Including Maintenance | Vania TM Hungria, MD, PhD | Clinica São Germano, São Paulo, Brazil

Oral Abstract | MM-355: Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in (D-VRd) Transplant-Eligible (TE) Patients With Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) in the Phase 3 PERSEUS Study | Meletios A Dimopoulos, MD | National and Kapodistrian University of Athens School of Medicine, Athens, Greece